AmyriAD Therapeutics Acquires Recognify Life Sciences, Expanding Its Clinical-Stage Cognition Pipeline with RL-007 (Inidascamine)

Summary

AmyriAD Therapeutics acquires Recognify Life Sciences in an all-share transaction, adding the clinical-stage cognition program RL-007 (Inidascamine) for Cognitive Impairment Associated with Schizophrenia to its pipeline. Recognify shareholders including atai Life Sciences become shareholders of AmyriAD.